Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RARE logo RARE
Upturn stock ratingUpturn stock rating
RARE logo

Ultragenyx (RARE)

Upturn stock ratingUpturn stock rating
$36.52
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: RARE (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

20 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $89.84

Year Target Price $89.84

Analyst’s Price TargetsFor last 52 week
$89.84Target price
Low$29.59
Current$36.52
high$60.37

Analysis of Past Performance

Type Stock
Historic Profit 34.1%
Avg. Invested days 39
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.45B USD
Price to earnings Ratio -
1Y Target Price 89.84
Price to earnings Ratio -
1Y Target Price 89.84
Volume (30-day avg) -
Beta 0.24
52 Weeks Range 29.59 - 60.37
Updated Date 06/30/2025
52 Weeks Range 29.59 - 60.37
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.83

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -93.04%
Operating Margin (TTM) -102.62%

Management Effectiveness

Return on Assets (TTM) -24.51%
Return on Equity (TTM) -377.06%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2995562697
Price to Sales(TTM) 5.85
Enterprise Value 2995562697
Price to Sales(TTM) 5.85
Enterprise Value to Revenue 5.07
Enterprise Value to EBITDA -6.46
Shares Outstanding 94542000
Shares Floating 90977303
Shares Outstanding 94542000
Shares Floating 90977303
Percent Insiders 3.46
Percent Institutions 98.71

Analyst Ratings

Rating 4.6
Target Price 89.84
Buy 6
Strong Buy 13
Buy 6
Strong Buy 13
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Ultragenyx

stock logo

Company Overview

overview logo History and Background

Ultragenyx Pharmaceutical Inc. was founded in 2010. It focuses on developing treatments for rare and ultra-rare genetic diseases. The company has grown through drug development, acquisitions, and partnerships.

business area logo Core Business Areas

  • Commercial Products: This segment focuses on the sales and marketing of approved therapies, including Crysvita, Dojolvi, Mepsevii, and Burokinumab.
  • Research and Development: This segment focuses on the development of treatments for rare genetic diseases.

leadership logo Leadership and Structure

Emil D. Kakkis, M.D., Ph.D., is the CEO and President. The company has a typical corporate structure with various departments headed by VPs reporting to the CEO.

Top Products and Market Share

overview logo Key Offerings

  • Crysvita (burosumab): Crysvita treats X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Revenue in 2023 was $773.4 million. Competitors include conventional phosphate and vitamin D therapies. Kyowa Kirin is a partner on this drug.
  • Dojolvi (triheptanoin): Dojolvi treats long-chain fatty acid oxidation disorders (LC-FAOD). Revenue in 2023 was $101.7 million. There are currently no direct competitors.
  • Mepsevii (vestronidase alfa): Mepsevii treats Mucopolysaccharidosis VII (MPS VII). Mepsevii revenue in 2023 was $46.6 million. There are currently no direct competitors.
  • Burokinumab: Burokinumab is in Phase 3 development for uncontrolled gout. No revenue until approval.

Market Dynamics

industry overview logo Industry Overview

The rare disease market is growing due to increased awareness, advances in genetic testing, and regulatory incentives. It is characterized by high unmet needs and orphan drug designations.

Positioning

Ultragenyx is a leader in developing and commercializing therapies for rare and ultra-rare genetic diseases. Its competitive advantage lies in its expertise in rare disease drug development and its established commercial infrastructure.

Total Addressable Market (TAM)

The rare disease market is projected to reach hundreds of billions of dollars. Ultragenyx is positioned to capture a significant share with its diverse pipeline and approved therapies.

Upturn SWOT Analysis

Strengths

  • Strong expertise in rare disease drug development
  • Established commercial infrastructure
  • Diverse product portfolio
  • Robust pipeline of investigational therapies

Weaknesses

  • Reliance on a small number of key products
  • High R&D expenses
  • Dependence on regulatory approvals
  • Potential for competition from larger pharmaceutical companies

Opportunities

  • Expanding into new rare disease indications
  • Acquiring or licensing new therapies
  • Partnering with other companies
  • Geographic expansion

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from biosimilars
  • Pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • LLY
  • VRTX

Competitive Landscape

Ultragenyx competes with large pharmaceutical companies and smaller biotech firms in the rare disease space. Its focus on ultra-rare diseases gives it a niche advantage.

Major Acquisitions

GeneTx Biotherapeutics

  • Year: 2020
  • Acquisition Price (USD millions): 76
  • Strategic Rationale: Acquired GeneTx to gain access to its GTX-101 program for Angelman syndrome.

Growth Trajectory and Initiatives

Historical Growth: Ultragenyx has experienced significant revenue growth driven by the commercialization of its products.

Future Projections: Analysts expect continued revenue growth driven by existing products and new product launches. Profitability is anticipated but subject to R&D success.

Recent Initiatives: The company has focused on expanding the indications for its existing products, advancing its pipeline, and pursuing strategic acquisitions.

Summary

Ultragenyx is a growing biopharmaceutical company focused on rare diseases with increasing revenues from its commercial products. It faces challenges in achieving profitability and managing R&D expenses. Successful pipeline development and strategic acquisitions will be key for its future growth. Competition is high as is risk of drug development setbacks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Ultragenyx SEC Filings (10-K, 10-Q)
  • Company Investor Relations
  • Analyst Reports
  • Company Website

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market data and analysis are subject to change and may not be accurate. Conduct thorough due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ultragenyx

Exchange NASDAQ
Headquaters Novato, CA, United States
IPO Launch date 2014-01-31
Founder, President, CEO & Director Dr. Emil D. Kakkis M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 1294
Full time employees 1294

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.